Canary Capital launches staked Injective ETF on Nasdaq
Share
Key points
- Canary Capital launched the Canary Staked INJ ETF (NASDAQ:INJC), giving US investors exchange-traded exposure to Injective (INJ).
- The fund seeks to earn additional INJ through proof-of-stake validation, with net rewards reflected in its value.
- The launch gives investors access through brokerage accounts without directly holding or managing INJ tokens.
Canary Capital has launched the Canary Staked INJ ETF (NASDAQ:INJC), bringing Injective (INJ) exposure to Nasdaq investors.
The fund tracks INJ’s price and seeks additional tokens through the network’s proof-of-stake validation process.
“The Canary Staked INJ ETF gives investors access to a blockchain purpose-built for finance through a familiar exchange-traded structure, while also enabling investors to benefit from potential staking rewards,” said Canary Capital Chief Executive Officer Steven McClurg.
Net staking rewards will contribute to the fund’s net asset value, giving shareholders indirect exposure to potential staking income.
“Investors can now gain exposure to INJ through the brokerage accounts they already use,” said Injective Foundation Co-Founder Eric Chen.
Injective supports onchain trading, tokenisation and financial applications through infrastructure that includes a fully onchain order-book module.
The network had tokenised more than $1 billion in assets and processed over 3.13 billion transactions by October 2026.
Following the update, INJ was trading up 3.2% at $8.28.
Frequently asked questions
More from Crypto
Leap launches Solana app for tokenised markets
Hyperliquid Strategies reports $621 million quarterly profit
Paraguay's Peña resigns after Ueno Bank collapse
Binance and Deribit cut SignalPlus API access
Samsung launches Solana-based USDC accounts in Wallet
Core Scientific targets Bitcoin mining exit as AI revenue grows
